Dora Wynchank1, Denise Bijlenga2, Aartjan T Beekman3, J J Sandra Kooij2,3, Brenda W Penninx3. 1. PsyQ Expertise Center Adult ADHD, Carel Reinierszkade 197, 2593 HR, The Hague, The Netherlands. d.wynchank@parnassiagroep.nl. 2. PsyQ Expertise Center Adult ADHD, Carel Reinierszkade 197, 2593 HR, The Hague, The Netherlands. 3. Department of Psychiatry, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
PURPOSE OF REVIEW: Insomnia is diagnosed when there is dissatisfaction with sleep quantity or quality. It has a prevalence in the general population ranging from 31 to 56%. Insomnia has previously been associated with adult attention-deficit/hyperactivity disorder (ADHD). In this review, we address three topics: (1) the cross-sectional relationship between ADHD and insomnia in adulthood, (2) the longitudinal relationship between ADHD and insomnia, and (3) insomnia as a side effect of pharmacological treatments for adult ADHD. RECENT FINDINGS: Three cross-sectional, clinical, and population studies report a prevalence of insomnia in ADHD adults ranging from 43 to 80%. Longitudinal evidence for a link between childhood-onset ADHD and insomnia at later age is mixed, with one study confirming and another study not supporting such a longitudinal association. In randomized, placebo-controlled trials, insomnia is reported significantly more often in the treatment arm than in the placebo arm. In varying percentages of trial participants, insomnia is a treatment-emergent adverse effect in triple-bead mixed amphetamine salts (40-45%), dasotraline (35-45%), lisdexamfetamine (10-19%), and extended-release methylphenidate (11%). Ten to seventeen percent of subjects in placebo-controlled trials of atomoxetine report insomnia, possibly related to poor metabolizer status. The mechanisms explaining the relationship between ADHD and sleep problems are incompletely understood, but both genetic and non-shared environmental influences may be involved. Adults with ADHD should be assessed for insomnia, which is frequently comorbid, and both conditions should be treated.
PURPOSE OF REVIEW: Insomnia is diagnosed when there is dissatisfaction with sleep quantity or quality. It has a prevalence in the general population ranging from 31 to 56%. Insomnia has previously been associated with adult attention-deficit/hyperactivity disorder (ADHD). In this review, we address three topics: (1) the cross-sectional relationship between ADHD and insomnia in adulthood, (2) the longitudinal relationship between ADHD and insomnia, and (3) insomnia as a side effect of pharmacological treatments for adult ADHD. RECENT FINDINGS: Three cross-sectional, clinical, and population studies report a prevalence of insomnia in ADHD adults ranging from 43 to 80%. Longitudinal evidence for a link between childhood-onset ADHD and insomnia at later age is mixed, with one study confirming and another study not supporting such a longitudinal association. In randomized, placebo-controlled trials, insomnia is reported significantly more often in the treatment arm than in the placebo arm. In varying percentages of trial participants, insomnia is a treatment-emergent adverse effect in triple-bead mixed amphetamine salts (40-45%), dasotraline (35-45%), lisdexamfetamine (10-19%), and extended-release methylphenidate (11%). Ten to seventeen percent of subjects in placebo-controlled trials of atomoxetine report insomnia, possibly related to poor metabolizer status. The mechanisms explaining the relationship between ADHD and sleep problems are incompletely understood, but both genetic and non-shared environmental influences may be involved. Adults with ADHD should be assessed for insomnia, which is frequently comorbid, and both conditions should be treated.
Authors: John Fayyad; Nancy A Sampson; Irving Hwang; Tomasz Adamowski; Sergio Aguilar-Gaxiola; Ali Al-Hamzawi; Laura H S G Andrade; Guilherme Borges; Giovanni de Girolamo; Silvia Florescu; Oye Gureje; Josep Maria Haro; Chiyi Hu; Elie G Karam; Sing Lee; Fernando Navarro-Mateu; Siobhan O'Neill; Beth-Ellen Pennell; Marina Piazza; José Posada-Villa; Margreet Ten Have; Yolanda Torres; Miguel Xavier; Alan M Zaslavsky; Ronald C Kessler Journal: Atten Defic Hyperact Disord Date: 2016-11-19
Authors: Bonnie A Fijal; Yingying Guo; Si G Li; Jonna Ahl; Taro Goto; Yoko Tanaka; Laura K Nisenbaum; Himanshu P Upadhyaya Journal: J Clin Pharmacol Date: 2015-06-14 Impact factor: 3.126
Authors: A Marije Boonstra; J J Sandra Kooij; Jaap Oosterlaan; Joseph A Sergeant; Jan K Buitelaar; Eus J W Van Someren Journal: Sleep Date: 2007-04 Impact factor: 5.849
Authors: A N Coogan; M Schenk; D Palm; A Uzoni; J Grube; A H Tsang; I Kolbe; N M McGowan; R Wandschneider; M Colla; H Oster; J Thome; F Faltraco Journal: Neuropsychopharmacology Date: 2019-02-06 Impact factor: 7.853
Authors: Deepika E Slawek; Madiha Syed; Chinazo O Cunningham; Chenshu Zhang; Jonathan Ross; Merrill Herman; Nancy Sohler; Haruka Minami; Frances R Levin; Julia H Arnsten; Joanna L Starrels Journal: J Psychiatr Res Date: 2021-12-02 Impact factor: 5.250
Authors: Sharon B Wigal; Tim Wigal; Mary Hobart; Jessica J Madera; Ross A Baker; Eva Kohegyi; Anthony McKinney; Timothy E Wilens Journal: Neuropsychiatr Dis Treat Date: 2020-06-08 Impact factor: 2.570